Pages that link to "Q45256524"

The following pages link to Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children (Q45256524):

Displaying 10 items.

• Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz (Q35547723) (← links)
• Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa (Q35846143) (← links)
• Bioactivation of chlorpyrifos by CYP2B6 variants (Q36462008) (← links)
• The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children (Q37030715) (← links)
• Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children (Q37519804) (← links)
• Population pharmacometrics in support of analgesics studies. (Q38175171) (← links)
• Pharmacokinetics of Efavirenz at a High Dose of 25 Milligrams per Kilogram per Day in Children 2 to 3 Years Old. (Q38377051) (← links)
• Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs. (Q38957969) (← links)
• Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin (Q40050910) (← links)
• Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites (Q90392223) (← links)